TC Biopharm launches cost reduction initiatives
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Workforce Reduction and Outsourcing Initiatives: TC BioPharm is transitioning to a decentralized model by outsourcing several functions, resulting in a workforce reduction of approximately 20 employees, primarily in production and quality divisions, which constitutes about half of the company's total headcount.
Cost Savings and Future Production Plans: The company aims to implement a CDMO model for production to meet increased demand for clinical trials, expecting to save around $2.1M in partial year 2025 and approximately $4.2M annually, while reducing its operational burn rate by 55% compared to 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
